- ¥136bn
- ¥128bn
- ¥19bn
Table: Peptidream -2018/19 parent results
Focus: As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff
Swiss stocks - Factors to watch on June 28
Brief: Kleo Pharmaceuticals Announces CD38 Targeting Antibody Recruiting Molecule To Treat Multiple Myeloma
Table: Peptidream - 9-MTH parent results
Table: Peptidream - 6-MTH parent results
Brief: Shionogi & Co Ltd Announces Agreements On Collaborative Research With Peptidream For New Peptide Drug Conjugate(Pdc) Discovery
Brief: Kleo Pharmaceuticals Secures $21 Mln To Advance Novel Small Molecule Cancer Immunotherapies
Brief: PeptiDream to invest $10 mln in Kleo Pharmaceuticals
Table: Peptidream - Q1 parent results
Brief: PeptiDream announces drug discovery and development agreement with Santen Pharmaceutical
Brief: PeptiDream to invest 200 mln yen in drug discovery venture
Table: Peptidream -2017/18 parent results
Brief: PeptiDream says licensing of Peptide Discovery Platform System Technology to Merck & Co., Inc., Kenilworth, N.J.,U.S.A.
Brief: PeptiDream announces expansion of discovery alliance with Genentech
Brief: PeptiDream says completion of technology transfer of Peptide Discovery Platform System to Shionogi
Table: Peptidream - 9-MTH parent results
Brief: PeptiDream to invest 1.8 bln yen in peptide drugs unit
Table: Peptidream - 6-MTH parent results